NEW YORK – Horiba Medical announced on Wednesday that its new generation of the Microsemi CRP hematology analyzer, the Microsemi CRP LC-767G, has received CE marking.
The new analyzer is more compact and has enhanced software and network connectivity with higher memory, the firm said in a statement. It also includes a new parameter, the Granulocytes-to-Lymphocytes Ratio.
The point-of-care analyzer was developed by Kyoto, Japan-based Horiba and provides a complete blood count and c-reactive protein in four minutes from between 10 and 18 microliters of capillary or venous blood samples, the company added.
Horiba said the analyzer could help with COVID-19 screening and monitoring because the quick CRP analysis "allows the screening of patient samples to quantify the presence of inflammation caused by bacterial, viral (e.g., COVID-19), parasites infections (e.g., malaria), and other treatable inflammatory diseases."